Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL8714807 | 0.81 | TSHR (0.48) | TSHRPPARDTP53TDP1CA1 | |
| SCHEMBL192086 | 0.81 | TSHR (0.48) | TSHRPPARDTP53TDP1CA1 | |
| SCHEMBL9961218 | 0.80 | TSHR (0.52) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL11545238 | 0.78 | TSHR (0.50) | TSHRPPARDTP53TDP1CA1 | |
| SCHEMBL17445781 | 0.78 | TSHR (0.42) | TSHRPPARDTP53TDP1CA1 | |
| SCHEMBL2855157 | 0.78 | TSHR (0.50) | TSHRPPARDTP53TDP1CA1 | |
| SCHEMBL2313241 | 0.76 | TSHR (0.48) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL2670250 | 0.76 | PPARD (0.50) | TSHRPPARDTP53TDP1CA1 | |
| SCHEMBL8714812 | 0.76 | TSHR (0.48) | TSHRPPARDTP53TDP1CA1 | |
| SCHEMBL16076961 | 0.76 | PPARD (0.52) | TSHRPPARDTP53TDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0839155-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1998-05-06 | — | — | EP | claimed |
| WO-1997004004-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1997-02-06 | — | — | WO | claimed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4719605-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GlaxoSmithKline Intellectual Property (No.4) Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2026-01-15 | — | — | US | disclosed |
| WO-2025262192-A1 | QUINAZOLINE DERIVATIVES SUITABLE FOR USE AS WERNER SYNDROME HELICASE PROTEIN INHIBITORS | BREAKPOINT THERAPEUTICS GMBH (DE) | 2025-12-26 | — | — | WO | disclosed |
| EP-4649081-A1 | SULFONYLVINYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-10-30 | — | — | US | disclosed |
| EP-3980400-B1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | UNIV EMORY (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025133395-A1 | BICYCLIC (HETERO)ARYLENE WRN INHIBITORY COMPOUNDS | FORX THERAPEUTICS AG (CH) | 2025-06-26 | — | — | WO | disclosed |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-06-12 | — | — | US | disclosed |
| EP-0906333-B1 | SUBSTRATES AND INHIBITORS OF PROTEOLYTIC ENZYMES | MEDIVIR UK LTD (GB) | 2001-07-25 | — | — | EP | disclosed |
| US-6034066-A | ANTIALLERGENS | PEPTIDE THERAPEUTICS LIMITED (GB) | 2000-03-07 | — | — | US | disclosed |
| EP-0906333-A2 | SUBSTRATES AND INHIBITORS OF PROTEOLYTIC ENZYMES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1999-04-07 | — | — | EP | disclosed |
| US-5776718-A | Reversible protease inhibitors | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0839155-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1998-05-06 | — | — | EP | disclosed |
| EP-0817778-A1 | REVERSIBLE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-01-14 | — | — | EP | disclosed |
| WO-1997040065-A2 | SUBSTRATES AND INHIBITORS OF PROTEOLYTIC ENZYMES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997004004-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1997-02-06 | — | — | WO | disclosed |
| WO-1996030353-A1 | REVERSIBLE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | TSHR 2799/4885PPARD 4787/4885TP53 905/4885 |
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | TSHR 3832/4885PPARD 3618/4885TP53 6/4885 |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | WRN, MSH2, MSH6 | TSHR 4153/4885PPARD 3762/4885TP53 108/4885 |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | TSHR 4064/4885PPARD 3372/4885TP53 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.